Details for Patent: 10,550,081

Which drugs does patent 10,550,081 protect, and when does it expire?

Patent 10,550,081 protects YUPELRI and is included in one NDA.

This patent has thirty-three patent family members in twenty-one countries.

Summary for Patent: 10,550,081

Title:	Crystalline freebase forms of a biphenyl compound
Abstract:	The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piper- idin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.
Inventor(s):	Woollam; Grahame (Basel, CH)
Assignee:	Theravance Biopharma R&D IP, LLC (South San Francisco, CA)
Application Number:	16/130,079
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,550,081
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 10,550,081

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mylan Ireland Ltd	YUPELRI	revefenacin	SOLUTION;INHALATION	210598-001	Nov 9, 2018		RX	Yes	Yes				Y

International Family Members for US Patent 10,550,081

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010273514
Brazil	112012000890
Canada	2765621
Canada	2989129